1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSickle Cell Disease Research and Treatment Demonstration Program is sponsored by Health Resources and Services Administration (HRSA). Supports projects that demonstrate innovative approaches to improving the quality of care for individuals with sickle cell disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar # View Grant Opportunity Forecast View similar opportunities Sickle Cell Disease Regional Care Excellence (SoRCE) Program Department of Health and Human Services Health Resources and Services Administration Note: This is a Forecasted Opportunity.
Document Type:Grants Notice Opportunity Number:HRSA-26-052 Opportunity Title:Sickle Cell Disease Regional Care Excellence (SoRCE) Program Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Category of Funding Activity:Health Expected Number of Awards:7 Assistance Listings:93.
365 -- Sickle Cell Treatment Demonstration Program Cost Sharing or Matching Requirement:No Forecasted Date:Dec 11, 2025 Last Updated Date:May 28, 2026 Estimated Post Date:Jun 09, 2026 Estimated Application Due Date:Jul 09, 2026 Electronically submitted applications must be submitted no later than 11:59 p. m. , ET, on the listed application due date.
Estimated Award Date:Aug 01, 2026 Estimated Project Start Date:Sep 01, 2026 Archive Date:Aug 30, 2026 Estimated Total Program Funding:$ 6,650,000 Eligible Applicants:Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Private institutions of higher education Additional Information on Eligibility:Hospitals or clinicsHealth centers.
## Additional Information Agency Name:Health Resources and Services Administration Description:Sickle Cell Disease Regional Care Excellence Program (SoRCE) is to improve the health of people with sickle cell disease (SCD) by expanding access to care, improving the quality of care, and tracking quality of life indicators. There are approximately 100,000 people in the United States with SCD.
Treatment starting in early childhood can prevent or reduce complications such as severe pain episodes, silent strokes, and premature death. Despite universal identification at birth, fewer than half of children with SCD receive needed treatment.
As these children become adolescents and transition to adulthood many are not appropriately identified as candidates for disease-modifying therapies, in part because their doctors are still learning how to use the latest treatments. The program is made up of seven regions with one award recipient per region serving as a Regional Coordinating Hub (RCH).
Each award recipient will work with clinical and community-based partners in their region and engage in continuous quality improvement (CQI) initiatives to improve access and quality of care. Link to Additional Information:[](https://www. grants.
gov/search-results-detail/360997) Grantor Contact Information:MCHB ## Similar Opportunities (identified by AI) HHS-2026-ACL-AOD-DFLA-0025 HHS-2026-ACF-ACYF-CU-0021 #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.
Unsaved changes will be lost.
According to the current listing, eligibility includes: Nonprofits, State/local governments, Universities, Hospitals. Confirm the full requirements in the official notice before applying.
Sickle Cell Disease Research and Treatment Demonstration Program is funded by Health Resources and Services Administration (HRSA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
HRSA-27-006 and HRSA-27-007 post September 18, 2026 and both close October 19 — $711.4 million across 189 awards for service areas that already have a health center in them. The incumbent is defending. Everyone else is holding a free option.
Read articleHRSA-27-099 offers $125 million for 357 awards of $350,000 each to health centers with an active H80 award, closing September 9, 2026. An identical FY2026 round closed June 9 with the same money, the same award count, and a September 1 award date. Here is what back-to-back rounds mean for winners and losers of the first one, and why the 120-day implementation clause is the real commitment.
Read articleOn September 4, 2026, HRSA awarded $11.2 million through the Rural Residency Planning and Development program to build 15 new physician residencies across 14 states. Since 2019 the program has invested nearly $77 million, producing 66 accredited programs and 818 approved positions. Here is what the conversion rate reveals, why the specialty mix is narrowing, and how to build a competitive application for the next cycle.
Read article